Pfizer is considering relocating its overseas manufacturing operations to existing facilities within the U.S., with the drug giant's CEO describing the potential move as a strategic shift aimed at mitigating the impact of proposed tariffs on pharmaceutical imports.
Ready to adapt: The Trump administration has threatened to impose a 25% tariff on pharmaceutical imports, prompting companies like Pfizer to reassess their manufacturing strategies. According to Pfizer CEO Albert Bourla, the company's robust U.S. manufacturing network puts it in a good position to adapt effectively to the potential policy change.
Capacity to onshore: Pfizer currently operates 10 manufacturing sites and two distribution centers across the United States. Bourla said the extensive infrastructure provides the company with the flexibility to transfer production from international sites to domestic facilities if necessary. He said Pfizer's U.S. manufacturing sites are operating at high capacity, which would facilitate any required transitions.
Big pharma responds: The potential tariffs are part of a broader initiative by President Donald Trump to bolster domestic manufacturing. Since taking office, Trump has urged pharmaceutical companies to increase their U.S.-based production. In February, he met with CEOs from major drugmakers, including Eli Lilly's David Ricks, to discuss industry concerns such as tariffs on drug imports. Following this meeting, Eli Lilly announced plans to invest $27 billion in new U.S. plants.
Up in the air: While President Trump has mentioned considering exemptions to reciprocal tariffs for certain industries, including pharmaceuticals, no definitive decisions have been made. This uncertainty has led companies like Pfizer to proactively explore strategies to safeguard their operations and maintain supply chain stability.
